QLARIS BIO
Qlaris Bio focuses on developing novel and innovative therapies for serious and debilitating ophthalmic diseases. Qlaris Bio is a spinout company of Qrativ, a biotechnology incubator formed as a joint venture between Mayo Clinic and inference, a pharmaceutical-focused artificial intelligence company. Its lead program is QLS-101, a novel compound invented at Mayo Clinic and the University of Minnesota. QLS-101, with its unique and first-in-class mechanism of action, may potentially serve as an ef... ficacious treatment for high unmet need conditions related to disturbances in intraocular pressure, including a sight-threatening and progressive Pediatric Rare Disease for which effective therapies remain elusive and limited. Qlaris Bio was founded in 2019 and is headquartered in Cambridge, Massachusetts.
QLARIS BIO
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2019-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.qlaris.bio
Total Employee:
1+
Status:
Active
Total Funding:
8.2 M USD
Current Advisors List
Current Employees Featured
Founder
Investors List
Mayo Clinic Ventures
Mayo Clinic Ventures investment in Series A - Qlaris Bio
Correlation Ventures
Correlation Ventures investment in Series A - Qlaris Bio
New Leaf Venture Partners
New Leaf Venture Partners investment in Series A - Qlaris Bio
Official Site Inspections
http://www.qlaris.bio
- Host name: 68.111.223.35.bc.googleusercontent.com
- IP address: 35.223.111.68
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Qlaris Bio"
About Us - qlaris.bio
Qlaris was founded upon a singular concept—that a comprehensive and complementary approach combining all aspects of scientific, medical, business, and strategic considerations …See details»
Qlaris Bio - Crunchbase Company Profile & Funding
Qlaris Bio is a clinical stage biotechnology company that develops innovative first-in-class therapies for patients suffering from serious and debilitating …See details»
Qlaris Bio Company Profile 2025: Valuation, Funding
Qlaris Bio General Information Description. Developer of novel therapies designed to treat serious and debilitating ophthalmic diseases. The company's …See details»
Qlaris Bio, Inc. - LinkedIn
Qlaris Bio, Inc. | 743 followers on LinkedIn. Qlaris Bio seeks to develop novel, innovative therapies for serious and debilitating ophthalmic diseases | At Qlaris, our lead program is QLS …See details»
Qlaris Bio - VentureRadar
Qlaris Bio is a spinout company of Qrativ, a biotechnology incubator formed as a joint venture between Mayo Clinic and nference, a pharmaceutical-focused artificial intelligence company. …See details»
Qlaris Bio - Funding, Financials, Valuation & Investors - Crunchbase
Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases. Search Crunchbase. Start Free Trial . Chrome Extension. ... How much funding has …See details»
Qlaris Bio - Updates, News, Events, Signals & Triggers - Crunchbase
Qlaris Bio focuses on developing first-in-class therapies for serious and debilitating ophthalmic diseases.See details»
Qlaris Bio Company Profile - Office Locations, Competitors ... - Craft
Qlaris Bio is a company developing therapies for ophthalmic diseases. Its main product is QLS-101, a compound that serves as a treatment for disturbances in intraocular pressure, …See details»
Qlaris Bio Completes $24 Million Series B Financing Round to …
Apr 30, 2024 Qlaris Bio, Inc. was founded in August 2019 with a singular focus: to develop novel, innovative therapies with first-in-class mechanisms of action to address serious and …See details»
Thurein Htoo Of Qlaris Bio: Five Things You Need To Create A
Jun 30, 2023 According to the World Health Organization (WHO), glaucoma is the second leading cause of blindness worldwide, with more than 80 million people currently diagnosed. …See details»
Qlaris Bio Completes $24 Million Series B Financing Round to …
Apr 30, 2024 Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma Business Wire Tue, Apr 30, 2024, …See details»
Qlaris Bio | CipherBio
Explore Qlaris Bio's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Invest In Qlaris Bio Stock | Buy Pre-IPO Shares | EquityZen
Qlaris Bio is a clinical stage biotechnology company founded on a relentless commitment to develop innovative first-in-class therapies that can make a truly impactful change for patients …See details»
Qlaris Bio - Work in biotech
Qlaris Bio is developing therapeutics to treat serious and debilitating ophthalmic diseases. Patients with certain ophthalmic diseases suffer a progressive and permanent loss of vision …See details»
Qlaris Bio Secures $24 Million Funding for Revolutionary …
May 1, 2024 Qlaris Bio, a biotechnology company specializing in ophthalmic diseases, secured $24 million in Series B financing. The round was co-led by Canaan and New Leaf Venture …See details»
Qlaris Bio - Contacts, Employees, Board Members, Advisors
Organization. Qlaris Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. Number of Board …See details»
Qlaris Bio Announces Positive Topline Data From Two Phase II
6 days ago Qlaris Bio will present a corporate update at the Glaucoma 360 New Horizons Forum 2025 on February 7 th in San Francisco, CA. The Osprey study ( NCT06016972 ), is a …See details»
Qlaris sees double as drug reduces eye pressure in ph. 2 trials
6 days ago Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and …See details»
News and Events - qlaris.bio
Annual awards program recognizes innovations and achievements in global biopharma Wellesley, Mass., September 28, 2022 – Qlaris Bio, Inc, a biotechnology company targeting high unmet …See details»
Qlaris Bio announces positive data from 2 clinical trials …
1 day ago Qlaris Bio has announced positive topline results from 2 phase II clinical trials investigating QLS‑111 in patients with primary open angle glaucoma (POAG) and ocular …See details»